Impact of is of lurane on malignant capability of ovarian cancer in vitro

British Journal of Anaesthesia

Volumn 114, Issue 5, 2015, Pages 831-839

  Luo, X ^a,b   Zhao, H ^b   Hennah, L ^b   Ning, J ^b   Liu, J ^a   Tu, H ^a   Ma, D ^b  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b Section of Anaesthetics Pain Medicine and Intensive Care Department of Surgery and Cancer   (United Kingdom)

Author keywords

anaesthetics; angiogenesis; insulin like growth factor; isoflurane; migration; ovarian cancer; proliferation

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; CYCLIN D; CYCLIN E; GELATINASE A; GELATINASE B; ISOFLURANE; KI 67 ANTIGEN; METALLOPROTEINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; VASCULOTROPIN; INHALATION ANESTHETIC AGENT; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS POTENTIAL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL DIVISION; CELL MOTION; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANESTHETICS, INHALATION; BLOTTING, WESTERN; CELL DIVISION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN VITRO TECHNIQUES; ISOFLURANE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84928894822     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu408     Document Type: Article

References (34)

1. Rose SL. Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer 2009; 19: 564-6
2. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105: 106-15
3. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130: 1237-50
4. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 2012; 109(Suppl 1): i17-28
5. Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth 2011; 106: 814-22
6. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109: 180-7
7. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-4
8. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82: 492-7
9. Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo-implications for angioprevention. Carcinogenesis 2012; 33: 385-93
10. Franks NP, Lieb WR. Temperature dependence of the potency of volatile general anesthetics: implications for in vitro experiments. Anesthesiology 1996; 84: 716-20
11. Zhao H, Luo X, Zhou Z, et al. Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats. Kidney Int 2014; 85: 112-23
12. Ash SA, Valchev GI, LooneyM, et al. Xenon decreases cell migration and secretion of a pro-angiogenesis factor in breast adenocarcinoma cells: comparison with sevoflurane. Br J Anaesth 2014; 113(Suppl. 1): i14-21
13. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensivemethodforanalysis of cell migration in vitro.Nat Protoc 2007; 2: 329-33
14. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 2006; 20: 1892-4
15. Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J Anaesth 2009; 103: 685-90
16. HanahanD, WeinbergRA. Hallmarksof cancer: thenext generation. Cell 2011; 144: 646-74
17. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8
18. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999; 13: 773-80
19. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22
20. Garzetti GG, Ciavattini A, Goteri G, et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56: 169-74
21. Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 2005; 192: 819-25
22. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10
23. Metheny-Barlow LJ, Li LY. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res 2003; 13: 309-17
24. Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS, Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000; 6: 750-65
25. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249-56
26. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007; 25: 346-54
27. Zhang L, Huang H, Cheng J, et al. Pre-treatment with isoflurane ameliorates renal ischemic-reperfusion injury in mice. Life Sci 2011; 88: 1102-7
28. Benzonana LL, Perry NJ, Watts HR, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology 2013; 119: 593-605
29. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32
30. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91: 513-7
31. Daponte A, Ioannou M, Mylonis I, et al. Prognostic significance of hypoxia-inducible factor alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 2008; 8: 335
32. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661-8
33. Suffee N, Hlawaty H, Meddahi-Pelle A, et al. RANTES/CCL5-induced pro-angiogenic effectsdependonCCR1, CCR5andglycosaminoglycans. Angiogenesis 2012; 15: 727-44
34. Looney M, Doran P, Buggy DJ. Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor beta in women undergoing anesthesia and surgery for breast cancer. Anesthesiology 2010; 113: 1118-25